Precision BioSciences Inc (DTIL) stock
DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/3058% above fair value
$7.05−0.23 (-3.16%)
Close on Nov 17, 2026Market cap $194.59MP/E –Yield –
Precision BioSciences r&d expenses
Research and development expenses are spending on new products and technology.
Precision BioSciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $53.32M, down 3.7% year over year. For fiscal 2025 it was $54.17M, down 9.0% from the year before. The highest annual figure on record is $115.24M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.17M | -9.0% |
| FY2024 | Dec 31, 2024 | $59.56M | +11.6% |
| FY2023 | Dec 31, 2023 | $53.38M | +15.7% |
| FY2022 | Dec 31, 2022 | $46.12M | -60.0% |
| FY2021 | Dec 31, 2021 | $115.24M | +17.5% |
| FY2020 | Dec 31, 2020 | $98.06M | +19.0% |
| FY2019 | Dec 31, 2019 | $82.42M | +82.7% |
| FY2018 | Dec 31, 2018 | $45.12M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.39M | -2.9% |
| Q1 FY2026 | Mar 31, 2026 | $13.11M | -3.5% |
| Q4 FY2025 | Dec 31, 2025 | $14.46M | -9.1% |
| Q3 FY2025 | Sep 30, 2025 | $13.35M | +2.0% |
| Q2 FY2025 | Jun 30, 2025 | $12.77M | -25.9% |
| Q1 FY2025 | Mar 31, 2025 | $13.59M | +1.8% |
| Q4 FY2024 | Dec 31, 2024 | $15.91M | +18.8% |
| Q3 FY2024 | Sep 30, 2024 | $13.08M | -17.5% |
| Q2 FY2024 | Jun 30, 2024 | $17.23M | +31.6% |
| Q1 FY2024 | Mar 31, 2024 | $13.34M | +20.8% |
| Q4 FY2023 | Dec 31, 2023 | $13.39M | +5.6% |
| Q3 FY2023 | Sep 30, 2023 | $15.85M | +34.8% |
| Q2 FY2023 | Jun 30, 2023 | $13.09M | -42.9% |
| Q1 FY2023 | Mar 31, 2023 | $11.05M | -44.7% |
| Q4 FY2022 | Dec 31, 2022 | $12.68M | -52.1% |
| Q3 FY2022 | Sep 30, 2022 | $11.76M | -54.7% |
| Q2 FY2022 | Jun 30, 2022 | $22.94M | -38.4% |
| Q1 FY2022 | Mar 31, 2022 | $19.97M | -22.0% |
| Q4 FY2021 | Dec 31, 2021 | $26.47M | +14.5% |
| Q3 FY2021 | Sep 30, 2021 | $25.94M | +4.3% |
| Q2 FY2021 | Jun 30, 2021 | $37.24M | +47.9% |
| Q1 FY2021 | Mar 31, 2021 | $25.59M | +2.9% |
| Q4 FY2020 | Dec 31, 2020 | $23.13M | +16.2% |
| Q3 FY2020 | Sep 30, 2020 | $24.87M | +25.7% |
| Q2 FY2020 | Jun 30, 2020 | $25.18M | +10.6% |
| Q1 FY2020 | Mar 31, 2020 | $24.88M | +24.6% |
| Q4 FY2019 | Dec 31, 2019 | $19.90M | +21.4% |
| Q3 FY2019 | Sep 30, 2019 | $19.79M | +103.3% |
| Q2 FY2019 | Jun 30, 2019 | $22.76M | +109.4% |
| Q1 FY2019 | Mar 31, 2019 | $19.96M | +145.9% |
| Q4 FY2018 | Dec 31, 2018 | $16.40M | – |
| Q3 FY2018 | Sep 30, 2018 | $9.74M | – |
| Q2 FY2018 | Jun 30, 2018 | $10.87M | – |
| Q1 FY2018 | Mar 31, 2018 | $8.12M | – |
See a number that looks wrong?